Establishment and Characterization of Transplantable, Luminescence Labeled Rat Renal Cell Carcinoma Cell Lines

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 2029-2035

  Kobayashi, Minoru ^a   Murakami, Takashi ^a   Uchibori, Ryosuke ^a   Chun, Nicole A L ^a   Kobayashi, Eiji ^a   Morita, Tatsuo ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

carcinoma, renal cell; cell line; kidney; luminescent proteins; models, animals

Indexed keywords

FIREFLY LUCIFERASE; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BEETLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER GROWTH; CELL COUNT; CELL GROWTH; CONTROLLED STUDY; IMMUNOCOMPETENCE; KIDNEY CARCINOMA; MALE; METASTASIS; NONHUMAN; PHOTON; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RENAL CELL CARCINOMA CELL LINE ACI RCC; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CARCINOMA, RENAL CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; KIDNEY NEOPLASMS; LUMINESCENCE; RATS; RATS, INBRED STRAINS; STATISTICS, NONPARAMETRIC;

EID: 77950512356     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.12.090     Document Type: Article

References (23)

1. Mulders P., Figlin R., deKernion J.B., et al. Renal cell carcinoma: recent progress and future directions. Cancer Res 57 (1997) 5189
2. Hutson T.E., and Quinn D.I. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?. Clin Genitourin Cancer 4 (2005) 181
3. Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13 (2007) 1098
4. Lyons S.K. Advances in imaging mouse tumour models in vivo. J Pathol 205 (2005) 194
5. Wiltrout R.H., Gregorio T.A., Fenton R.G., et al. Cellular and molecular studies in the treatment of murine renal cancer. Semin Oncol 22 (1995) 9
6. Nogawa M., Yuasa T., Kimura S., et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217 (2005) 243
7. Verheul H.M., Hammers H., van Erp K., et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13 (2007) 4201
8. Kato Y., Yoshimura K., Shin T., et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13 (2007) 4538
9. Okada S., Hamazaki S., Ebina Y., et al. Nephrotoxicity and induction of the renal adenocarcinoma by ferric-nitrilotriacetate (Fe-NTA) in rats. In: Urushizaki I. (Ed). Structure and Function of Iron Storage and Transport Proteins (1983), Elsevier Science, Amsterdam 473-478
10. Kobayashi M., Okada T., Murakami T., et al. Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems. Urology 70 (2007) 1230
11. Lu X., Kallinteris N.L., Li J., et al. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother 52 (2003) 592
12. Jenkins D.E., Oei Y., Hornig Y.S., et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20 (2003) 733
13. Rehemtulla A., Stegman L.D., Cardozo S.J., et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2 (2000) 491
14. Inoue Y., Tojo A., Sekine R., et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 33 (2006) 557
15. Brubaker J.O., Thompson C.M., Morrison L.A., et al. Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus. J Immunol 157 (1996) 1598
16. Gambotto A., Dworacki G., Cicinnati V., et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 7 (2000) 2036
17. Hakamata Y., Murakami T., and Kobayashi E. "Firefly rats" as an organ/cellular source for long-term in vivo bioluminescent imaging. Transplantation 81 (2006) 1179
18. Jeon Y.H., Choi Y., Kang J.H., et al. Immune response to firefly luciferase as a naked DNA. Cancer Biol Ther 6 (2007) 781
19. Rabinovich B.A., Ye Y., Etto T., et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 105 (2008) 14342
20. Peter C., Kielstein J.T., Clarke-Katzenberg R., et al. A novel bioluminescent tumor model of human renal cancer cell lines: an in vitro and in vivo characterization. J Urol 177 (2007) 2342
21. Smakman N., Martens A., Kranenburg O., et al. Validation of bioluminescence imaging of colorectal liver metastases in the mouse. J Surg Res 122 (2004) 225
22. Ronnen E.A., Kondagunta G.V., Ishill N., et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24 (2006) 543
23. Bellon S.F., Kaplan-Lefko P., Yang Y., et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 283 (2008) 2675